Technology | March 03, 2014

FDA Clears Admedus's CardioCel

Ademedus CardioCel Stem Cell Therapy

March 3, 2014 — The U.S. Food and Drug Administration (FDA) cleared Admedus’s CardioCel, a tissue product to repair and treat a range of cardiovascular and vascular defects. The company is looking to complement its existing product launch in Europe with preparation for initial sales in the United States.

The intended use of CardioCel in the United States is in pericardial closure and for the repair of cardiac and vascular defects in both adults and paediatrics.

Admedus can sell CardioCel in both Europe and the US and will pursue market approvals in Asia and other jurisdictions.

CardioCel is engineered by the group’s ADAPT tissue engineering process. It intends to be a durable, pure collagen scaffold that avoids calcification, supports native cell infiltration, growth and differentiation and which promotes a regenerative healing process.

CardioCel has shown that it does not calcify and can facilitate autologous tissue regeneration once surgically implanted, while retaining strength and natural elasticity. CardioCel is a ready to use, off the shelf product that has the potential to prevent follow up surgeries for patients because of its anti-calcification and regenerative properties.

For more information: www.admedus.com 

Related Content

News | Stem Cell Therapies

November 19, 2021 — Stem cell therapy helped to reduce the number of heart attacks, strokes and death among people with ...

Home November 19, 2021
Home
News | Stem Cell Therapies

October 28, 2021 – The first patient has been treated in a new trial using stem cell therapy to treat chronic myocardial ...

Home October 28, 2021
Home
Videos | Stem Cell Therapies

Mechanical engineering Professor Nathan Sniadecki, associate chair for research and infrastructure, mechanical ...

Home October 04, 2021
Home
Feature | Stem Cell Therapies | By Simon H. Stertzer, M.D.

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections ...

Home May 11, 2021
Home
Feature | Stem Cell Therapies | By Andy Freeberg

The University of Washington (UW) in Seattle has developed engineered heart tissue that beats. Though minuscule, the ...

Home February 25, 2021
Home
News | Stem Cell Therapies

August 22, 2019 — Renovacor Inc, a preclinical-stage biopharmaceutical company, announced the successful completion of ...

Home August 22, 2019
Home
News | Stem Cell Therapies

May 20, 2019 – Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that stem cells derived from ...

Home May 20, 2019
Home
News | Stem Cell Therapies

April 19, 2019 — Aziyo Biologics Inc. announced the publication of results from its landmark RECON study in the Journal ...

Home April 19, 2019
Home
News | Stem Cell Therapies

March 4, 2019 — The U.S. Food and Drug Administration (FDA) recently finalized two guidance documents regarding ...

Home March 04, 2019
Home
News | Stem Cell Therapies

February 1, 2019 — A team of Rutgers scientists have taken an important step toward the goal of making diseased hearts ...

Home February 01, 2019
Home
Subscribe Now